Compare CVRX & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVRX | VYGR |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.0M | 222.4M |
| IPO Year | 2021 | 2015 |
| Metric | CVRX | VYGR |
|---|---|---|
| Price | $7.31 | $3.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $13.17 | ★ $17.00 |
| AVG Volume (30 Days) | 371.4K | ★ 600.2K |
| Earning Date | 02-04-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $55,969,000.00 | $31,316,000.00 |
| Revenue This Year | $11.91 | N/A |
| Revenue Next Year | $15.28 | $71.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.44 | N/A |
| 52 Week Low | $4.30 | $2.65 |
| 52 Week High | $17.78 | $5.96 |
| Indicator | CVRX | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 48.89 |
| Support Level | $6.96 | $3.86 |
| Resistance Level | $6.09 | $4.22 |
| Average True Range (ATR) | 0.81 | 0.25 |
| MACD | 0.17 | 0.02 |
| Stochastic Oscillator | 60.17 | 61.76 |
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.